Drug
Liposomal Amphotericin B
Liposomal Amphotericin B: highest development phase Post-Market, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| liposomal amphotericin B (AmBisome®) NCT00386997 | Post-Market | Fungal Infection |
Latest
No recent events.
Follow Liposomal Amphotericin B on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.